Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Enzalutamide Tablets, available in 40 mg and 80 mg strengths. This significant approval marks a pivotal moment for the company, expanding its portfolio of cancer treatments and positioning it for a more substantial presence in the global […]
In a significant development for patients undergoing bone marrow or kidney transplants, Zydus Lifesciences Limited has been granted tentative approval by the United States Food and Drug Administration (USFDA) for its Letermovir tablets in 240 mg and 480 mg formulations. This approval marks a crucial step in preventing disease caused by cytomegalovirus (CMV) in these […]
In a significant development for the pharmaceutical industry, Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited, has secured final approval from the United States Food and Drug Administration (USFDA) to market its combination drug, Finasteride and Tadalafil Capsules USP, 5 mg/5 mg. This approval, announced recently, positions Zydus as the inaugural approved applicant for […]